BioSpace News Archive

Known to be one of the most common types of joint diseases, Osteoarthritis is a degenerative disease of the joint involving the joint lining, cartilage, underlying bone, and ligaments.

Nicox SA, an international ophthalmology company, announced that Jean-Francois Labbé, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022.

The inaugural ZAODX World Conference on Early Detection of Cancer was successfully held at the Chimelong International Conference Center in Guangzhou from July 15-17, 2022.

AbbVie announced that the European Commission has approved RINVOQ®, an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs.

ACM Biolabs announced that the first subject has been dosed in the first–in–human Phase 1 trial of its clinical candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein vaccine with broad protection against variants of concerns, including delta and omicron demonstrated in a variety of preclinical studies.

Second Sight Medical Products, Inc., a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced results of its annual meeting held on July 27, 2022, where the quorum was present.

Seegene Inc. took part in the 2022 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Chicago between July 26-28.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.

Enanta Pharmaceuticals, Inc . today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally administered single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-235 in healthy adult subjects.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open.